164 related articles for article (PubMed ID: 12416736)
41. In vitro resistance of leukaemic blasts to prednisolone in bcr-abl positive childhood acute lymphoblastic leukaemia.
Gupta M; Kumar A; Dabadghao S
Indian J Med Res; 2002 Dec; 116():268-72. PubMed ID: 12807155
[TBL] [Abstract][Full Text] [Related]
42. Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs.
Kaspers GJ; Pieters R; Van Zantwijk CH; Van Wering ER; Van Der Does-Van Den Berg A; Veerman AJ
Blood; 1998 Jul; 92(1):259-66. PubMed ID: 9639525
[TBL] [Abstract][Full Text] [Related]
43. Effect of the Philadelphia chromosome on minimal residual disease in acute lymphoblastic leukemia.
Brisco MJ; Sykes PJ; Dolman G; Neoh SH; Hughes E; Peng LM; Tauro G; Ekert H; Toogood I; Bradstock K; Morley AA
Leukemia; 1997 Sep; 11(9):1497-500. PubMed ID: 9305604
[TBL] [Abstract][Full Text] [Related]
44. Clinical and cell biological features related to cellular drug resistance of childhood acute lymphoblastic leukemia cells.
Kaspers GJ; Pieters R; Van Zantwijk CH; Van Wering ER; Veerman AJ
Leuk Lymphoma; 1995 Nov; 19(5-6):407-16. PubMed ID: 8590840
[TBL] [Abstract][Full Text] [Related]
45. Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of Philadelphia chromosome-negative cells in chronic myelogenous leukemia.
Kantarjian HM; Talpaz M; LeMaistre CF; Spinolo J; Spitzer G; Yau J; Dicke K; Jagannath S; Deisseroth AB
Cancer; 1991 Jun; 67(12):2959-65. PubMed ID: 1675151
[TBL] [Abstract][Full Text] [Related]
46. Poor treatment outcome of Philadelphia chromosome-positive pediatric acute lymphoblastic leukemia despite intensive chemotherapy.
Uckun FM; Nachman JB; Sather HN; Sensel MG; Kraft P; Steinherz PG; Lange B; Hutchinson R; Reaman GH; Gaynon PS; Heerema NA
Leuk Lymphoma; 1999 Mar; 33(1-2):101-6. PubMed ID: 10194126
[TBL] [Abstract][Full Text] [Related]
47. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG).
van der Does-van den Berg A; van Wering ER; Suciu S; Solbu G; van 't Veer MB; Rammeloo JA; de Koning J; van Zanen GE
Am J Pediatr Hematol Oncol; 1989; 11(2):125-33. PubMed ID: 2665546
[TBL] [Abstract][Full Text] [Related]
48. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
49. Outcome of treatment in adults with Philadelphia chromosome-positive and/or BCR-ABL--positive acute lymphoblastic leukemia-retrospective analysis of Polish Adult Leukemia Group (PALG).
Wrzesień-Kuś A; Robak T; Pluta A; Zwolińska M; Wawrzyniak E; Wierzbowska A; Skotnicki A; Jakubas B; Hołowiecki J; Nowak K; Kuliczkowski K; Mazur G; Haus O; Dmoszyńska A; Adamczyk-Cioch M; Jedrzejczak WW; Paluszewska M; Konopka L; Pałynyczko G
Ann Hematol; 2006 Jun; 85(6):366-73. PubMed ID: 16523310
[TBL] [Abstract][Full Text] [Related]
50. Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia.
Pane F; Cimino G; Izzo B; Camera A; Vitale A; Quintarelli C; Picardi M; Specchia G; Mancini M; Cuneo A; Mecucci C; Martinelli G; Saglio G; Rotoli B; Mandelli F; Salvatore F; Foà R;
Leukemia; 2005 Apr; 19(4):628-35. PubMed ID: 15744351
[TBL] [Abstract][Full Text] [Related]
51. Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia.
Pavlovsky C; Chan O; Talati C; Pinilla-Ibarz J
Future Oncol; 2019 Jan; 15(3):257-269. PubMed ID: 30251548
[TBL] [Abstract][Full Text] [Related]
52. Resistance to glucocorticoids in childhood acute lymphoblastic leukemia: impact of relationship between ex vivo sensitivity and in vivo concentration on risk factor analysis.
Styczynski J; Koltan A; Wysocki M
Neoplasma; 2006; 53(2):168-73. PubMed ID: 16575474
[TBL] [Abstract][Full Text] [Related]
53. In vitro activity of imatinib in cells from patients with adult acute lymphoblastic leukemia.
Hallböök H; Barbany G; Aleskog A; Björnberg A; Larsson R; Sundström C; Lindhagen E
Anticancer Drugs; 2005 Jul; 16(6):631-4. PubMed ID: 15930891
[TBL] [Abstract][Full Text] [Related]
54. Multiple drug resistance protein (MDR-1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) gene expression in childhood acute lymphoblastic leukemia.
Valera ET; Scrideli CA; Queiroz RG; Mori BM; Tone LG
Sao Paulo Med J; 2004 Jul; 122(4):166-71. PubMed ID: 15543372
[TBL] [Abstract][Full Text] [Related]
55. Lineage involvement by BCR/ABL in Ph+ lymphoblastic leukemias: chronic myelogenous leukemia presenting in lymphoid blast vs Ph+ acute lymphoblastic leukemia.
Anastasi J; Feng J; Dickstein JI; Le Beau MM; Rubin CM; Larson RA; Rowley JD; Vardiman JW
Leukemia; 1996 May; 10(5):795-802. PubMed ID: 8656674
[TBL] [Abstract][Full Text] [Related]
56. Corticosteroid resistance is increased in lymphoblasts from adults compared with children: preliminary results of in vitro drug sensitivity study in adults with acute lymphoblastic leukaemia.
Maung ZT; Reid MM; Matheson E; Taylor PR; Proctor SJ; Hall AG
Br J Haematol; 1995 Sep; 91(1):93-100. PubMed ID: 7577660
[TBL] [Abstract][Full Text] [Related]
57. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment.
Holleman A; Cheok MH; den Boer ML; Yang W; Veerman AJ; Kazemier KM; Pei D; Cheng C; Pui CH; Relling MV; Janka-Schaub GE; Pieters R; Evans WE
N Engl J Med; 2004 Aug; 351(6):533-42. PubMed ID: 15295046
[TBL] [Abstract][Full Text] [Related]
58. The dose related effect of steroids on blast reduction rate and event free survival in children with acute lymphoblastic leukemia.
Yetgin S; Cetin M
Leuk Lymphoma; 2003 Mar; 44(3):489-95. PubMed ID: 12688320
[TBL] [Abstract][Full Text] [Related]
59. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
Ribera JM; Ortega JJ; Oriol A; Granada I; Hernández-Rivas JM; Parody R; Bethencourt C; Rivas C; Bastida P; del Potro E; González-Valentín ME; Moreno MJ; Besalduch J; Fernández-Calvo J; Tormo M; Arias J; Molinés A; Sanz MA; Maldonado J; Millá F; Feliu E; San Miguel JF;
Haematologica; 2002 Feb; 87(2):154-66. PubMed ID: 11836166
[TBL] [Abstract][Full Text] [Related]
60. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study.
Yeoh AE; Ariffin H; Chai EL; Kwok CS; Chan YH; Ponnudurai K; Campana D; Tan PL; Chan MY; Kham SK; Chong LA; Tan AM; Lin HP; Quah TC
J Clin Oncol; 2012 Jul; 30(19):2384-92. PubMed ID: 22614971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
